Table 2. Demographic data of patients with ototoxicity included for meta-analysis.
Cases/Total | Ethnicity | Age (y) | Types of cancer | Gender of cases | Cumulative dose | Cranial irradiation | Otoprotectant | Vincristine | Aminoglycocide | |
N | Median | Male % | Median (mg/m2) | % | used | antibiotics | ||||
Ross et al.6 | 106/162 | Mixed population | 6 | Different cancers | 67.0% | 400 mg/m2 | 18.50% | No information | Yes | Yes |
Pussegoda et al.7 | 87/155 | Mixed population | 6 | Different cancers | 49.4% | 400 mg/m2 | 18% | No information | Yes | Yes |
Yang et al., radiation cohort8 | 131/195 | Mixed population | 7 | Medulloblastoma | 68.8%* | 300 mg/m2* | 100%* | Yes | Yes | No information |
Yang et al., no radiation8 | 35/38 | Mixed population | 8 | Medulloblastoma | 65.0% | 500 mg/m2 | 0 | Yes | Yes | No information |
Hagleitner, this study | 22/80 | Dutch ancestry | 15 | Osteosarcoma | 40.0% | 500 mg/m2 | 0 | No | Yes | No |
Patino-Garcia, this study | 18/34 | European ancestry | 12 | Osteosarcoma | 55.3% | 500 mg/m2 | 0 | No | Yes | Yes |
*data of total group as published by Yang et al. |